Tag Archives: Pfizer vaccine trial

Why the number ‘3’ may make you rethink Covid hysteria, by Simon Black

Simon Black makes strong points about Covid hysteria using the date from the Pfizer vaccine trial. From Black at sovereignman.com:

Yesterday I promised to explain why the number three is among the most compelling data points discovered so far in Covid-19 research.

And it’s something that you most likely won’t see in the mainstream media, even though the data is right there in the FDA’s research.

Covid has clearly been THE most heavily researched topic of 2020. Google Scholar shows roughly 90,000 scientific studies and academic papers on SARS-CoV-2 and COVID-19 that were published this year, which is a great testament to how quickly researchers can mobilize.

Many of these studies, however, were limited in nature. They were small-scale, involving only a handful of test subjects. Or they relied upon data from numerous, disparate sources, which introduced a lack of uniformity into the experiment.

But late last week, the FDA published its analysis of the Pfizer/BionTech COVID-19 vaccine trial results, called BNT162b2.

And the results are extremely valuable:

1- The study was very large, involving tens of thousands of people;

2- The participants came from all walks of life and highly diverse genetic compositions;

3- The rules and protocols were completely uniform across the entire experiment.

This is quite rare. Of the nearly 90,000 COVID-19 studies this year, very few meet these criteria.

Perhaps more importantly, there was no funny arithmetic involved, like how the government and media tend to count anyone who sets foot in a hospital or mortuary as Covid-related.

I told you yesterday that the vaccine results are very promising: only 8 people out of 20,033 who received two full doses of the vaccine ended up testing positive for COVID-19.

And perhaps even better, ZERO out of the 805 subjects over the age 75 (who received the vaccine) tested positive for COVID.

So Pfizer has clearly done something extraordinary here.

Continue reading→